Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia

April 29, 2024

https://www.globenewswire.com/news-release/2024/04/29/2871126/0/en/Alterity-Therapeutics-Presents-New-Data-Demonstrating-Potential-of-ATH434-to-Treat-Rare-Neurodegenerative-Disease-Friedreich-s-Ataxia.html

–   New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron   –

MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that important new data on its lead drug candidate ATH434 was presented at the World Orphan Drug Congress USA 2024 in Boston, MA.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.